Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3
Gilead and Arcellx’s early trial data on their multiple myeloma cell therapy show that patients saw no cases of certain delayed neurotoxicities, which are associated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
